# Immune Thrombocytopenia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/immune-thrombocytopenia

> 5 upcoming FDA catalysts in immune Thrombocytopenia: Wayrilz (rilzabrutinib, SNY) on November 2026 (primary completion); INCA000585 (INCY) on Sep to Dec 2027 (topline data readout); INCA000585 (INCY) on September 2027 (primary completion); Wayrilz (rilzabrutinib, SNY) on Nov 2027 to Feb 2028 (topline data readout); and 1 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2026 to Feb 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216079)) |
| November 2026 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216079)) |
| Sep to Dec 2027 | [INCA000585 topline data readout](https://sec-api.dev/pdufa/inca000585) | INCY | Immune Thrombocytopenia | scheduled | "NCT07104565 (Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-23 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104565)) |
| September 2027 | [INCA000585 primary completion](https://sec-api.dev/pdufa/inca000585) | INCY | Immune Thrombocytopenia | scheduled | "NCT07104565 (Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-23 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104565)) |
| Nov 2027 to Feb 2028 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007962)) |
| November 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007962)) |

## Drugs

- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib) (SNY)
- [INCA000585](https://sec-api.dev/pdufa/inca000585) (INCY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/immune-thrombocytopenia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Immune Thrombocytopenia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/immune-thrombocytopenia

```bibtex
@misc{secapidev_indications_immune_thrombocytopenia_20261116,
  title        = {Immune Thrombocytopenia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/immune-thrombocytopenia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_immune_thrombocytopenia_20261116","title":"Immune Thrombocytopenia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/immune-thrombocytopenia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
